Clinical Trials Logo

Filter by:
NCT ID: NCT05590793 Active, not recruiting - Clinical trials for Metastatic Prostate Cancer

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Start date: November 17, 2022
Phase: Phase 3
Study type: Interventional

The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.

NCT ID: NCT05590572 Not yet recruiting - Osteosarcoma Clinical Trials

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Start date: January 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 study evaluating safety, tolerability, and efficacy of Sulfatinib in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed osteosarcoma ( combination Sulfatinib).

NCT ID: NCT05590442 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Risk Model of Cognitive Impairment in Diabetes

Start date: September 1, 2022
Phase:
Study type: Observational

Development and validation of a risk model for predicting the risk of mild cognitive impairment among individuals of type 2 diabetes.

NCT ID: NCT05590416 Recruiting - Adalimumab Clinical Trials

A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

Start date: June 1, 2021
Phase:
Study type: Observational

This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease

NCT ID: NCT05590377 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

iinnovate-3
Start date: January 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose. Another aim of this study is to learn more about the characteristics of modakafusp alfa.

NCT ID: NCT05590286 Recruiting - Clinical trials for Helicobacter Pylori Infection

A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection

VATH-1
Start date: June 1, 2022
Phase: Phase 4
Study type: Interventional

The treatment of helicobacter pylori is very important. The routine treatment is quadruple therapy. In recent years, double therapy has appeared and the curative effect is fair. However, antacid generally uses proton pump inhibitor. The proton pump inhibitor needs double dose to achieve good antacid curative effect. The effect of vonoprazan used for inhibiting gastric acid is better than proton pump inhibitor. At present, many studies use vonoprazan instead of common proton pump inhibitor, but almost all use double dose of vonoprazan. In the previous study, we found that the effect of double dose of proton pump inhibitor can be achieved with 20mg QD of vonoprazan. Therefore, in this study, 20mg QD of vonoprazan was used to replace the double dose of proton pump inhibitor to observe the antibacterial effect of vonoprazan on Helicobacter pylori.

NCT ID: NCT05590221 Recruiting - B-cell Lymphoma Clinical Trials

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Start date: January 3, 2023
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to estimate the efficacy of Relmacabtagene Autoleucel in participants with high-risk large B-cell lymphoma.

NCT ID: NCT05589961 Recruiting - Clinical trials for Glioblastoma Multiforme

Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme

Start date: October 2022
Phase: Early Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety of an innovative integrated treatment regimen for recurrent glioblastoma , including patients with recurrent glioblastoma multiforme.

NCT ID: NCT05589480 Completed - Pancreatic Cancer Clinical Trials

Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection

PaC
Start date: August 1, 2022
Phase:
Study type: Observational

Recurrence of Pancreatic Cancer(PCa) is a multifactorial event. Based on the clinicopathological characteristics and imaging data of patients with PCa, the investigators used image processing and machine learning algorithms to build a more comprehensive and robust model, and added some unused features to explore its clinical application value. A retrospective analysis of patients with PCa who underwent radical resection at Zhejiang Cancer Hospital (Hangzhou, China) from January 2013 to December 2020. The database was extracted from the preoperative demographics, blood markers, and surgical pathology information of patients undergoing radical PCa surgery in the investigators' hospital. The investigators used the PyRadiomics platform to extract image features.

NCT ID: NCT05589454 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds

Start date: January 2023
Phase: Phase 4
Study type: Interventional

This study is the first and largest secondary prevention trial about lipid-lowering therapy for acute ischemic stroke patients at high-risk of intracranial hemorrhage. The primary hypothesis of this study is: excessive reduction in serum lipid levels by intensive statin therapy in acute ischemic stroke patients with cerebral microbleeds can increase the risk of intracranial hemorrhage. This study will shed light on new clinical decisions regarding the long-term serum lipid management in these patients with dilemma in clinical practice.